Intest Res.  2017 Jan;15(1):38-67. 10.5217/ir.2017.15.1.38.

Second Korean guidelines for the management of Crohn's disease

Affiliations
  • 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • 2Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea. sky@amc.seoul.kr
  • 3Department of Internal Medicine, Inje University College of Medicine Ilsan Paik Hospital, Goyang, Korea.
  • 4Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 5Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
  • 6Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
  • 7Department of Internal Medicine, The Catholic University of Korea College of Medicine, Suwon, Korea.
  • 8Department of Surgery, Hallym University College of Medicine, Chuncheon, Korea.
  • 9Center for Preventive Medicine and Public Health, Seoul National University Bundang Hospital, Seongnam, Korea.

Abstract

Crohn's disease (CD) is a chronic, progressive, and disabling inflammatory bowel disease (IBD) with an uncertain etiopathogenesis. CD can involve any site of the gastrointestinal tract from the mouth to the anus, and is associated with serious complications, such as bowel strictures, perforations, and fistula formation. The incidence and prevalence rates of CD in Korea are still lower compared with those in Western countries, but they have been rapidly increasing during the recent decades. Although there are no definitive curative modalities for CD, various medical and surgical therapies have been applied for the treatment of this disease. Concerning CD management, there have been substantial discrepancies among clinicians according to their personal experience and preference. To suggest recommendable approaches to the diverse problems of CD and to minimize the variations in treatment among physicians, guidelines for the management of CD were first published in 2012 by the IBD Study Group of the Korean Association for the Study of Intestinal Diseases. These are the revised guidelines based on updated evidence, accumulated since 2012. These guidelines were developed by using mainly adaptation methods, and encompass induction and maintenance treatment of CD, treatment based on disease location, treatment of CD complications, including stricture and fistula, surgical treatment, and prevention of postoperative recurrence. These are the second Korean guidelines for the management of CD and will be continuously revised as new evidence is collected.

Keyword

Crohn disease; Management; Guideline

MeSH Terms

Anal Canal
Constriction, Pathologic
Crohn Disease*
Fistula
Gastrointestinal Tract
Humans
Incidence
Inflammatory Bowel Diseases
Intestinal Diseases
Korea
Mouth
Prevalence
Recurrence

Cited by  11 articles

Mechanism-based Drug Therapy of Inflammatory Bowel Disease With Special Reference to Rheumatic Disease
Jae Jun Park
J Rheum Dis. 2020;27(3):128-135.    doi: 10.4078/jrd.2020.27.3..

Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
Jae Hee Cheon
J Rheum Dis. 2021;28(1):4-16.    doi: 10.4078/jrd.2021.28.1.4.

Monitoring Disease Activity: How and When?
Kang-Moon Lee
Korean J Gastroenterol. 2018;71(2):69-73.    doi: 10.4166/kjg.2018.71.2.69.

Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience
Dai Jung, Sunghee Lee, Insook Jeong, Seak Hee Oh, Kyung Mo Kim
Pediatr Gastroenterol Hepatol Nutr. 2017;20(4):236-243.    doi: 10.5223/pghn.2017.20.4.236.

How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?
You Sun Kim
Korean J Gastroenterol. 2018;71(2):74-80.    doi: 10.4166/kjg.2018.71.2.74.

Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?
Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jung Nam Kim, Na Rae Lee, Jae Hee Cheon
Intest Res. 2020;18(1):85-95.    doi: 10.5217/ir.2019.00055.

The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
Intest Res. 2021;19(1):62-70.    doi: 10.5217/ir.2019.09156.

Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park
Intest Res. 2022;20(4):452-463.    doi: 10.5217/ir.2021.00125.

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
Jong Pil Im
Intest Res. 2017;15(2):147-148.    doi: 10.5217/ir.2017.15.2.147.

Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
Way-Seah Lee, Najib Azmi, Ruey-Terng Ng, Sik-Yong Ong, Sasheela Sri La Ponnampalavanar, Sanjiv Mahadeva, Ida Hilmi
Intest Res. 2017;15(4):524-528.    doi: 10.5217/ir.2017.15.4.524.

Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
Intest Res. 2023;21(3):339-352.    doi: 10.5217/ir.2022.00135.


Reference

1. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2008; 14:542–549. PMID: 17941073.
Article
2. Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008; 103:3167–3182. PMID: 19086963.
Article
3. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016; 14:111–119. PMID: 27175111.
Article
4. Ye BD, Yang SK, Shin SJ, et al. Guidelines for the management of Crohn's disease. Korean J Gastroenterol. 2012; 59:141–179. PMID: 22387837.
Article
5. Ye BD, Yang SK, Shin SJ, et al. Guidelines for the management of Crohn's disease. Intest Res. 2012; 10:26–66.
Article
6. D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011; 106:199–212. PMID: 21045814.
7. Orlando A, Armuzzi A, Papi C, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis. 2011; 43:1–20. PMID: 20843756.
Article
8. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011; 60:571–607. PMID: 21464096.
9. National Clinical Guideline Centre. National institute for health and clinical excellence: guidance. Crohn's disease: management in adults, children and young people. London: Royal College of Physicians (UK);2012. p. 1–398. Accessed July 23, 2015. Available at: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0068978/.
10. Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT. AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013; 145:1459–1463. PMID: 24267474.
Article
11. Ueno F, Matsui T, Matsumoto T, et al. Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. J Gastroenterol. 2013; 48:31–72. PMID: 23090001.
Article
12. Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut. 2014; 63:1381–1392. PMID: 24951257.
Article
13. Ooi CJ, Makharia GK, Hilmi I, et al. Asia-Pacific consensus statements on Crohn's disease. Part 2: management. J Gastroenterol Hepatol. 2016; 31:56–68. PMID: 25819311.
Article
14. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. rating the quality of evidence. J Clin Epidemiol. 2011; 64:401–406. PMID: 21208779.
Article
15. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336:924–926. PMID: 18436948.
Article
16. Lee KM, Kim YS, Seo GS, Kim TO, Yang SK. IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Use of thiopurines in inflammatory bowel disease: a consensus statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 2015; 13:193–207. PMID: 26130993.
Article
17. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008; 336:1049–1051. PMID: 18467413.
Article
18. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009; 136:441–450.e1. PMID: 19109962.
Article
19. Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. Inflamm Bowel Dis. 2009; 15:1460–1466. PMID: 19266566.
Article
20. Sorrentino D, Terrosu G, Paviotti A, et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab. A pilot study. Dig Dis Sci. 2012; 57:1341–1348. PMID: 22252267.
Article
21. Yoshida K, Fukunaga K, Ikeuchi H, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis. 2012; 18:1617–1623. PMID: 22081474.
Article
22. Armuzzi A, Felice C, Papa A, et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. J Crohns Colitis. 2013; 7:e623–e629. DOI: 10.1016/j.crohns.2013.04.020. PMID: 23810678.
Article
23. Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. Am J Gastroenterol. 2013; 108:1731–1742. PMID: 24019080.
Article
24. Regueiro M, Feagan BG, Zou B, et al. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection. Gastroenterology. 2016; 150:1568–1578. PMID: 26946343.
25. Sachar DB. Ten common errors in the management of inflammatory bowel disease. Inflamm Bowel Dis. 2003; 9:205–209. PMID: 12792229.
Article
26. Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009; 104:465–483. PMID: 19174807.
Article
27. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015; 110:1324–1338. PMID: 26303131.
28. Wolters FL, Russel MG, Stockbrügger RW. Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther. 2004; 20:483–496. PMID: 15339320.
Article
29. Park SH, Yang SK, Park SK, et al. Long-term prognosis of Crohn's disease and its temporal change between 1981 and 2012: a hospital-based cohort study from Korea. Inflamm Bowel Dis. 2014; 20:488–494. PMID: 24412992.
Article
30. Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B. Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD). Hospitalisations and surgery in Crohn's disease. Gut. 2012; 61:622–629. PMID: 22267595.
Article
31. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010; 105:289–297. PMID: 19861953.
Article
32. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis. 2011; 17:471–478. PMID: 20725943.
Article
33. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006; 130:650–656. PMID: 16530505.
Article
34. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol. 2008; 43:948–954. PMID: 19086165.
Article
35. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010; 4:28–62. PMID: 21122489.
Article
36. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70:439–444. PMID: 1248701.
37. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980; 1:514. PMID: 6102236.
Article
38. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis. 2010; 4:7–27. PMID: 21122488.
Article
39. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002; 122:512–530. PMID: 11832465.
Article
40. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117:761–769. PMID: 10500056.
Article
41. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359:1541–1549. PMID: 12047962.
Article
42. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010; 8:357–363. PMID: 20096379.
Article
43. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006; 55(Suppl 1):i1–i15. PMID: 16481628.
Article
44. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000; 6:8–15. PMID: 10701144.
Article
45. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55:749–753. PMID: 16698746.
Article
46. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001; 49:777–782. PMID: 11709511.
Article
47. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8:244–250. PMID: 12131607.
Article
48. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2010; (12):CD008870. DOI: 10.1002/14651858.CD008870. PMID: 21154400.
Article
49. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984; 86:249–266. PMID: 6140202.
Article
50. Anthonisen P, Barany F, Folkenborg O, et al. The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease: a controlled double-blind study. Scand J Gastroenterol. 1974; 9:549–554. PMID: 4153646.
Article
51. Van Hees PA, Van Lier HJ, Van Elteren PH, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut. 1981; 22:404–409. PMID: 6114023.
Article
52. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993; 104:1293–1301. PMID: 8482443.
Article
53. Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology. 1999; 116:521–526. PMID: 10029609.
Article
54. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004; 2:379–388. PMID: 15118975.
Article
55. Seow CH, Benchimol EI, Steinhart AH, Griffiths AM, Otley AR. Budesonide for Crohn's disease. Expert Opin Drug Metab Toxicol. 2009; 5:971–979. PMID: 19611401.
Article
56. Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008; (3):CD000296. DOI: 10.1002/14651858.CD000296.pub3. PMID: 18646064.
Article
57. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease: the Global Budesonide Study Group. Gut. 1997; 41:209–214. PMID: 9301500.
Article
58. Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease: German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol. 1996; 8:905–909. PMID: 8889459.
59. Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008; (2):CD006792. DOI: 10.1002/14651858.CD006792.pub2. PMID: 18425970.
Article
60. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979; 77:847–869. PMID: 38176.
Article
61. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2003; (4):CD000301. DOI: 10.1002/14651858.CD000301. PMID: 14583917.
Article
62. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337:1029–1035. PMID: 9321530.
Article
63. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130:323–333. PMID: 16472588.
Article
64. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005; 129:807–818. PMID: 16143120.
Article
65. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357:228–238. PMID: 17634458.
Article
66. Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011; 9:670–678.e3. PMID: 21642014.
Article
67. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med. 1995; 123:132–142. PMID: 7778826.
68. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2013; (4):CD000545. DOI: 10.1002/14651858.CD000545.pub4. PMID: 23633304.
Article
69. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362:1383–1395. PMID: 20393175.
Article
70. Kopylov U, Al-Taweel T, Yaghoobi M, et al. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis. 2014; 8:1632–1641. PMID: 25067824.
Article
71. Goodsell DS. The molecular perspective: methotrexate. Oncologist. 1999; 4:340–341. PMID: 10476546.
Article
72. Rajagopalan PT, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammes GG. Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics. Proc Natl Acad Sci U S A. 2002; 99:13481–13486. PMID: 12359872.
Article
73. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am. 1997; 23:739–755. PMID: 9361153.
Article
74. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease: the North American Crohn's Study Group Investigators. N Engl J Med. 1995; 332:292–297. PMID: 7816064.
75. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology. 1999; 46:1724–1729. PMID: 10430331.
76. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol. 1997; 92:2203–2209. PMID: 9399753.
77. Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014; 13:24–30. PMID: 23792214.
Article
78. Siegel CA, Melmed GY. Predicting response to Anti-TNF agents for the treatment of Crohn's disease. Therap Adv Gastroenterol. 2009; 2:245–251.
Article
79. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132:52–65. PMID: 17241859.
Article
80. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol. 2002; 97:2357–2363. PMID: 12358256.
Article
81. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology. 2002; 123:707–713. PMID: 12198696.
Article
82. Ho GT, Smith L, Aitken S, et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther. 2008; 27:308–315. PMID: 18081730.
Article
83. Swaminath A, Ullman T, Rosen M, Mayer L, Lichtiger S, Abreu MT. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients. Aliment Pharmacol Ther. 2009; 29:273–278. PMID: 19006540.
Article
84. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011; 33:987–995. PMID: 21366636.
Article
85. Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015; 21:182–197. PMID: 25222660.
Article
86. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009; 137:1628–1640. PMID: 19664627.
Article
87. Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016; 22:1999–2015. PMID: 27135483.
Article
88. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014; 147:618–627.e3. PMID: 24859203.
Article
89. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016; 375:1946–1960. PMID: 27959607.
90. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146:829–838. PMID: 17470824.
Article
91. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2005; (1):CD003715. DOI: 10.1002/14651858.CD003715.pub2. PMID: 15674913.
Article
92. Steinhart AH, Forbes A, Mills EC, Rodgers-Gray BS, Travis SP. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2007; 25:1389–1399. PMID: 17539978.
Article
93. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106:590–599. PMID: 21407179.
Article
94. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995; 37:674–678. PMID: 8549944.
Article
95. Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013; 145:1464–1478.e1-5. PMID: 24267475.
Article
96. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008; (1):CD006893. DOI: 10.1002/14651858.CD006893. PMID: 18254120.
Article
97. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008; 135:1493–1499. PMID: 18848553.
Article
98. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357:239–250. PMID: 17634459.
Article
99. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004; 126:402–413. PMID: 14762776.
Article
100. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4:1248–1254. PMID: 16931170.
Article
101. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006; 63:433–442. PMID: 16500392.
Article
102. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008; 134:1861–1868. PMID: 18440315.
Article
103. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010; 59:1363–1368. PMID: 20587545.
Article
104. Viazis N, Koukouratos T, Anastasiou J, et al. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation. Eur J Gastroenterol Hepatol. 2015; 27:436–441. PMID: 25874518.
Article
105. Kierkus J, Iwanczak B, Wegner A, et al. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease. J Pediatr Gastroenterol Nutr. 2015; 60:580–585. PMID: 25564804.
Article
106. Jones JL, Kaplan GG, Peyrin-Biroulet L, et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn's disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2015; 13:2233–2240.e1-2. PMID: 26142167.
Article
107. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease: North American Crohn's Study Group Investigators. N Engl J Med. 2000; 342:1627–1632. PMID: 10833208.
Article
108. Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2014; (8):CD006884. DOI: 10.1002/14651858.CD006884.pub3. PMID: 25157445.
Article
109. Nathan DM, Iser JH, Gibson PR. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J Gastroenterol Hepatol. 2008; 23:954–958. PMID: 17559377.
Article
110. Mayberry JF, Lobo A, Ford AC, Thomas A. NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people. Aliment Pharmacol Ther. 2013; 37:195–203. PMID: 23151246.
Article
111. Regueiro M, Siemanowski B, Kip KE, Plevy S. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis. 2007; 13:1093–1099. PMID: 17480021.
Article
112. Sandborn WJ, Colombel JF, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011; 17:141–151. PMID: 20848500.
Article
113. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013; 369:711–721. PMID: 23964933.
Article
114. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006; 12(Suppl 1):S3–S9. PMID: 16378007.
Article
115. Stocchi L, Milsom JW, Fazio VW. Long-term outcomes of laparoscopic versus open ileocolic resection for Crohn's disease: follow-up of a prospective randomized trial. Surgery. 2008; 144:622–627. PMID: 18847647.
Article
116. Eshuis EJ, Slors JF, Stokkers PC, et al. Long-term outcomes following laparoscopically assisted versus open ileocolic resection for Crohn's disease. Br J Surg. 2010; 97:563–568. PMID: 20175126.
Article
117. Eshuis EJ, Stokkers PC, Bemelman WA. Decision-making in ileocecal Crohn's disease management: surgery versus pharmacotherapy. Expert Rev Gastroenterol Hepatol. 2010; 4:181–189. PMID: 20350265.
Article
118. Wagtmans MJ, Verspaget HW, Lamers CB, van Hogezand RA. Clinical aspects of Crohn's disease of the upper gastrointestinal tract: a comparison with distal Crohn's disease. Am J Gastroenterol. 1997; 92:1467–1471. PMID: 9317064.
119. Mottet C, Juillerat P, Pittet V, et al. Upper gastrointestinal Crohn's disease. Digestion. 2007; 76:136–140. PMID: 18239405.
Article
120. Miehsler W, Püspök A, Oberhuber T, Vogelsang H. Impact of different therapeutic regimens on the outcome of patients with Crohn's disease of the upper gastrointestinal tract. Inflamm Bowel Dis. 2001; 7:99–105. PMID: 11383598.
Article
121. Hanauer SB, Sandborn W. Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2001; 96:635–643. PMID: 11280528.
Article
122. Travis SP, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006; 55(Suppl 1):i16–i35. PMID: 16481629.
Article
123. Matsui T, Hatakeyama S, Ikeda K, Yao T, Takenaka K, Sakurai T. Long-term outcome of endoscopic balloon dilation in obstructive gastroduodenal Crohn's disease. Endoscopy. 1997; 29:640–645. PMID: 9360875.
Article
124. Matsui T, Ikeda K, Tsuda S, et al. Long-term outcome of endoscopic balloon dilation in obstructive gastrointestinal Crohn's disease: a prospective long-term study. Diagn Ther Endosc. 2000; 6:67–75. PMID: 18493528.
Article
125. Singh VV, Draganov P, Valentine J. Efficacy and safety of endoscopic balloon dilation of symptomatic upper and lower gastrointestinal Crohn's disease strictures. J Clin Gastroenterol. 2005; 39:284–290. PMID: 15758621.
Article
126. Tonelli F, Alemanno G, Bellucci F, Focardi A, Sturiale A, Giudici F. Symptomatic duodenal Crohn's disease: is strictureplasty the right choice? J Crohns Colitis. 2013; 7:791–796. PMID: 23165121.
Article
127. Vader JP, Froehlich F, Juillerat P, et al. Appropriate treatment for Crohn's disease. Methodology and summary results of a multidisciplinary international expert panel approach: EPACT. Digestion. 2006; 73:237–248. PMID: 16940727.
Article
128. Thomas-Gibson S, Brooker JC, Hayward CM, Shah SG, Williams CB, Saunders BP. Colonoscopic balloon dilation of Crohn's strictures: a review of long-term outcomes. Eur J Gastroenterol Hepatol. 2003; 15:485–488. PMID: 12702904.
129. Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006; 101:1030–1038. PMID: 16606351.
Article
130. Condino G, Calabrese E, Zorzi F, et al. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study. Dig Liver Dis. 2013; 45:258–262. PMID: 23195667.
Article
131. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999; 340:1398–1405. PMID: 10228190.
Article
132. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index: McMaster IBD Study Group. J Clin Gastroenterol. 1995; 20:27–32. PMID: 7884173.
133. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003; 125:1508–1530. PMID: 14598268.
Article
134. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002; 122:875–880. PMID: 11910338.
Article
135. Cheon JH, Kim YS, Ye BD, et al. Crohn's Disease Clinical Network and Cohort (CONNECT) study: the first step toward nationwide multicenter research of Crohn's disease in Korea. Intest Res. 2014; 12:173–175. PMID: 25349589.
Article
136. Jung YS, Park DI, Ye BD, et al. Long-term clinical outcomes of urban versus rural environment in Korean patients with Crohn's disease: results from the CONNECT study. J Crohns Colitis. 2015; 9:246–251. PMID: 25602024.
Article
137. Kim B, Cheon JH, Moon HJ, et al. Crohn's disease prognosis and early immunomodulator therapy: results from the CONNECT study. J Gastroenterol Hepatol. 2016; 31:126–132. PMID: 26406334.
Article
138. Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology. 1980; 79:599.
Article
139. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology. 1982; 83:383–387. PMID: 7084615.
Article
140. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol. 1984; 79:533–540. PMID: 6741906.
141. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009; 15:17–24. PMID: 18668682.
Article
142. Levien DH, Surrell J, Mazier WP. Surgical treatment of anorectal fistula in patients with Crohn's disease. Surg Gynecol Obstet. 1989; 169:133–136. PMID: 2756461.
143. Schwartz DA, Maltz BE. Treatment of fistulizing inflammatory bowel disease. Gastroenterol Clin North Am. 2009; 38:595–610. PMID: 19913204.
Article
144. Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther. 2003; 18:1113–1120. PMID: 14653831.
Article
145. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol. 1998; 93:442–448. PMID: 9517654.
Article
146. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci. 1994; 39:374–380. PMID: 8313821.
Article
147. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003; 125:380–388. PMID: 12891539.
Article
148. Mahadevan U, Marion JF, Present DH. Fistula response to methotrexate in Crohn's disease: a case series. Aliment Pharmacol Ther. 2003; 18:1003–1008. PMID: 14616166.
Article
149. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350:876–885. PMID: 14985485.
Article
150. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009; 58:940–948. PMID: 19201775.
Article
151. Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010; 32:1228–1239. PMID: 20955442.
Article
152. Echarri A, Castro J, Barreiro M, Carpio D, Pereira S, Lorenzo A. Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn's disease patients with infliximab failure. J Crohns Colitis. 2010; 4:654–660. PMID: 21122576.
Article
153. Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014; 63:292–299. PMID: 23525574.
Article
154. Yassin NA, Askari A, Warusavitarne J, et al. Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn's disease. Aliment Pharmacol Ther. 2014; 40:741–749. PMID: 25115149.
Article
155. Regueiro M. The role of endoscopy in the evaluation of fistulizing Crohn's disease. Gastrointest Endosc Clin N Am. 2002; 12:621–633. PMID: 12486948.
Article
156. Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA. The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther. 2003; 17:1145–1151. PMID: 12752351.
Article
157. Guillem JG, Roberts PL, Murray JJ, Coller JA, Veidenheimer MC, Schoetz DJ Jr. Factors predictive of persistent or recurrent Crohn's disease in excluded rectal segments. Dis Colon Rectum. 1992; 35:768–772. PMID: 1644001.
Article
158. Rehg KL, Sanchez JE, Krieger BR, Marcet JE. Fecal diversion in perirectal fistulizing Crohn's disease is an underutilized and potentially temporary means of successful treatment. Am Surg. 2009; 75:715–718. PMID: 19725296.
Article
159. Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016; 388:1281–1290. PMID: 27477896.
Article
160. Lee WY, Park KJ, Cho YB, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula. Stem Cells. 2013; 31:2575–2581. PMID: 23404825.
Article
161. Amiot A, Setakhr V, Seksik P, et al. Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID. Am J Gastroenterol. 2014; 109:1443–1449. PMID: 25091063.
Article
162. de la Poza G, López-Sanroman A, Taxonera C, et al. Genital fistulas in female Crohn's disease patients: clinical characteristics and response to therapy. J Crohns Colitis. 2012; 6:276–280. PMID: 22405162.
163. Sands BE, Blank MA, Patel K, van Deventer SJ. ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004; 2:912–920. PMID: 15476155.
Article
164. Zhang W, Zhu W, Li Y, et al. The respective role of medical and surgical therapy for enterovesical fistula in Crohn's disease. J Clin Gastroenterol. 2014; 48:708–711. PMID: 24457944.
Article
165. Hastings JW, Garg M, Lynn ET, Divino CM. Surgical repair of ileovesical fistulas: long-term complications, quality of life, and patient satisfaction. Am Surg. 2014; 80:1207–1211. PMID: 25513918.
Article
166. Gervais DA, Hahn PF, O'Neill MJ, Mueller PR. Percutaneous abscess drainage in Crohn disease: technical success and short- and long-term outcomes during 14 years. Radiology. 2002; 222:645–651. PMID: 11867780.
Article
167. Gutierrez A, Lee H, Sands BE. Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease. Am J Gastroenterol. 2006; 101:2283–2289. PMID: 17032194.
Article
168. Feagins LA, Holubar SD, Kane SV, Spechler SJ. Current strategies in the management of intra-abdominal abscesses in Crohn's disease. Clin Gastroenterol Hepatol. 2011; 9:842–850. PMID: 21679776.
Article
169. Lee H, Kim YH, Kim JH, et al. Nonsurgical treatment of abdominal or pelvic abscess in consecutive patients with Crohn's disease. Dig Liver Dis. 2006; 38:659–664. PMID: 16423568.
Article
170. Sahai A, Bélair M, Gianfelice D, Coté S, Gratton J, Lahaie R. Percutaneous drainage of intra-abdominal abscesses in Crohn's disease: short and long-term outcome. Am J Gastroenterol. 1997; 92:275–278. PMID: 9040205.
171. Garcia JC, Persky SE, Bonis PA, Topazian M. Abscesses in Crohn's disease: outcome of medical versus surgical treatment. J Clin Gastroenterol. 2001; 32:409–412. PMID: 11319312.
Article
172. Yamaguchi A, Matsui T, Sakurai T, et al. The clinical characteristics and outcome of intraabdominal abscess in Crohn's disease. J Gastroenterol. 2004; 39:441–448. PMID: 15175942.
Article
173. Kim DH, Cheon JH, Moon CM, et al. Clinical efficacy of nonsurgical treatment of Crohn's disease-related intraabdominal abscess. Korean J Gastroenterol. 2009; 53:29–35. PMID: 19158468.
174. Nguyen DL, Sandborn WJ, Loftus EV Jr, et al. Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2012; 10:400–404. PMID: 22155562.
Article
175. Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013; 145:996–1006. PMID: 23896172.
Article
176. McLeod RS. Surgery for inflammatory bowel diseases. Dig Dis. 2003; 21:168–179. PMID: 14571114.
Article
177. Thirlby RC, Land JC, Fenster LF, Lonborg R. Effect of surgery on health-related quality of life in patients with inflammatory bowel disease: a prospective study. Arch Surg. 1998; 133:826–832. PMID: 9711955.
178. Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003; 125:320–327. PMID: 12891531.
Article
179. Marchal L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther. 2004; 19:749–754. PMID: 15043515.
Article
180. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis. 2010; 4:63–101. PMID: 21122490.
181. Post S, Herfarth C, Böhm E, et al. The impact of disease pattern, surgical management, and individual surgeons on the risk for relaparotomy for recurrent Crohn's disease. Ann Surg. 1996; 223:253–260. PMID: 8604905.
Article
182. Tan JJ, Tjandra JJ. Laparoscopic surgery for Crohn's disease: a meta-analysis. Dis Colon Rectum. 2007; 50:576–585. PMID: 17380366.
Article
183. Bharadwaj S, Fleshner P, Shen B. Therapeutic armamentarium for stricturing Crohn's disease: medical versus endoscopic versus surgical approaches. Inflamm Bowel Dis. 2015; 21:2194–2213. PMID: 25985249.
184. Williams JG, Wong WD, Rothenberger DA, Goldberg SM. Recurrence of Crohn's disease after resection. Br J Surg. 1991; 78:10–19. PMID: 1998847.
Article
185. Ye BD, Yang SK, Cho YK, et al. Clinical features and long-term prognosis of Crohn's disease in Korea. Scand J Gastroenterol. 2010; 45:1178–1185. PMID: 20560811.
Article
186. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990; 99:956–963. PMID: 2394349.
Article
187. De Cruz P, Kamm MA, Hamilton AL, et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet. 2015; 385:1406–1417. PMID: 25542620.
Article
188. Yamamoto T, Watanabe T. Strategies for the prevention of postoperative recurrence of Crohn's disease. Colorectal Dis. 2013; 15:1471–1480. PMID: 23809911.
Article
189. Koilakou S, Sailer J, Peloschek P, et al. Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn's disease after ileocolic resection. Inflamm Bowel Dis. 2010; 16:198–203. PMID: 19504611.
Article
190. Minordi LM, Vecchioli A, Poloni G, Guidi L, De Vitis I, Bonomo L. Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn's disease: CT findings and correlation with endoscopy. Eur Radiol. 2009; 19:2432–2440. PMID: 19415289.
Article
191. Paredes JM, Ripollés T, Cortés X, et al. Contrast-enhanced ultrasonography: usefulness in the assessment of postoperative recurrence of Crohn's disease. J Crohns Colitis. 2013; 7:192–201. PMID: 22542055.
Article
192. Papay P, Ignjatovic A, Karmiris K, et al. Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis. 2013; 7:653–669. PMID: 23562672.
Article
193. Boschetti G, Laidet M, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn's disease. Am J Gastroenterol. 2015; 110:865–872. PMID: 25781366.
Article
194. Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology. 2015; 148:938–947.e1. PMID: 25620670.
Article
195. Fornaro R, Caratto E, Caratto M, et al. Post-operative recurrence in Crohn's disease. Critical analysis of potential risk factors: an update. Surgeon. 2015; 13:330–347. PMID: 26049657.
Article
196. Ford AC, Khan KJ, Talley NJ, Moayyedi P. 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106:413–420. PMID: 20717106.
Article
197. Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus EV Jr. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. Gastroenterology. 2015; 148:64–76.e2. PMID: 25263803.
Article
198. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015; 13:847–858.e4. PMID: 24879926.
Article
Full Text Links
  • IR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr